Selank: A Tuftsin-Derived Anxiolytic Peptide for GAD and Stress Modulation

This content is provided by Superpower Health for educational and informational purposes only. Selank is currently unavailable through Superpower due to FDA Category 2 classification. Selank is not FDA-approved for any indication in the United States. It is approved for use only in the Russian Federation. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

For decades, the dominant pharmacological answer to anxiety has been a benzodiazepine: fast-acting, sedating, and with a well-documented dependence profile. Millions of people have lived with that tradeoff. The search for alternatives that preserve anxiolytic efficacy without the sedation and dependence has been one of the quieter frontiers in psychopharmacology research. Selank emerged from that search, in a laboratory in Moscow, as a heptapeptide with an unusual pedigree: it derives structurally from tuftsin, an immunopeptide the human body already produces.

Here is what Selank is, what the Russian clinical data shows, and where its regulatory status stands as of April 2026.

Key Takeaways

• Regulatory Status: Not FDA-approved for any indication in the United States. Approved in the Russian Federation for generalized anxiety disorder and neurasthenia. As of April 2026, classified as an FDA Category 2 bulk drug substance; compounding is restricted pending further review.
• Research Stage: Clinically studied in Russia with human trial data available; no Western RCTs; not replicated in independent Western populations
• Availability: Currently unavailable through most US compounding pharmacies due to Category 2 classification; regulatory status may change
• Prescribing information: View compound reference data (PubChem CID 11765600)
• How it works: Acts as a positive allosteric modulator of GABA binding and modulates enkephalin and BDNF expression.
• What the research shows: Russian clinical data report anxiolytic activity in generalized anxiety disorder, with no sedation observed in the comparator-controlled trial; numeric effect sizes versus benzodiazepine comparators were not reported in the English-language abstract, and no Western RCTs have replicated these findings.

Where Selank Comes From and How It Works

Origin and discovery

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, the same institution responsible for Semax, another neuroactive peptide from the same research lineage. Selank is a structural analog of tuftsin, an endogenous tetrapeptide (Thr-Lys-Pro-Arg) produced by enzymatic cleavage of immunoglobulin G. Tuftsin was known to have immunomodulatory activity; selank extends that structure and adds a Pro-Gly-Pro C-terminal sequence that significantly increases stability and alters CNS activity. Development focused on creating an anxiolytic compound that would sidestep the sedation and physical dependence associated with benzodiazepines.

Proposed mechanisms

The most accessible English-language mechanism paper on selank's pharmacology, published in Protein and Peptide Letters in 2018 by Vyunova, Andreeva, and colleagues, used radioligand-receptor analysis to show that selank acts as a positive allosteric modulator of GABA binding at GABA-A receptors without directly engaging the benzodiazepine site. This distinction matters: benzodiazepines bind directly to the receptor and can suppress natural GABA-A function over time. Selank enhances GABA-A sensitivity rather than replacing the endogenous signal. A 2016 rat study by Volkova, Shadrina, and colleagues published in Frontiers in Pharmacology analyzed 84 neurotransmission-related genes in rat frontal cortex following a 300 μg/kg dose of selank or GABA. Forty-five of the 84 genes showed significant expression changes at 1 hour post-administration and 22 at 3 hours, with a positive correlation between selank- and GABA-induced changes at 1 hour — providing a molecular correlate consistent with allosteric GABAergic modulation.

Beyond GABAergic activity, selank influences the enkephalin-opioid system. Work by Konstantinopolsky, Chernyakova, and colleagues, published in Bulletin of Experimental Biology and Medicine in 2022, found that a single intraperitoneal dose of selank (0.3 mg/kg) attenuated aversive signs of naloxone-precipitated morphine withdrawal in outbred rats — reducing the total withdrawal index by approximately 39.6% with particular efficacy against convulsive reactions, ptosis, and posture disorders — at an effect level comparable to diazepam 2 mg/kg. This supports the hypothesis that part of selank's anxiolytic activity flows through opioid-system modulation rather than GABA alone. A 2017 study by Kasian, Kolomin, and colleagues in Behavioural Neurology showed that selank enhanced the anxiolytic effect of diazepam in a chronic mild stress rat model, supporting the framing that selank potentiates benzodiazepine activity through complementary pathways rather than duplicating their receptor action.

A third mechanism involves brain-derived neurotrophic factor. Inozemtseva and colleagues demonstrated in 2008, in Doklady Biological Sciences, that intranasal selank administration regulates BDNF expression in the rat hippocampus in vivo. BDNF supports neuronal plasticity and is implicated in mood regulation and memory consolidation. A 2019 study by Kolik and colleagues in Bulletin of Experimental Biology and Medicine found that selank (0.3 mg/kg intraperitoneally for 7 days) prevented memory and attention impairment during alcohol withdrawal in rats with 30 weeks of chronic ethanol exposure (p<0.01 in the object recognition test), and prevented ethanol-induced elevation of BDNF in the hippocampus and prefrontal cortex (p<0.05). Discrimination-index magnitudes were not reported in the English abstract. Broader transcriptomic work by Kolomin and colleagues, reported in 2010 in Doklady Biochemistry and Biophysics, showed that a single intranasal dose of selank produced measurable gene expression changes in both the rat hippocampus and spleen, consistent with the compound's dual CNS and peripheral immune activity. A 2013 follow-up in Zhurnal Vysshei Nervnoi Deyatelnosti by Kolomin, Agapova, and colleagues extended that finding to tuftsin-analog-specific hippocampal transcriptome changes relevant to anxiety and memory biology.

Preclinical cognition and memory evidence

Outside its anxiolytic profile, selank has an older preclinical literature examining cognition and memory consolidation. A foundational 2002 study by Kozlovskii and Danchev in Zhurnal Vysshei Nervnoi Deyatelnosti imeni I.P. Pavlova reported that selank at 300 μg/kg significantly increased correct responses and reduced errors in active-avoidance conditioning (p<0.05) in rats with initially low learning capacity, with effects observable after a single dose and a peak on day 3 of training in normal rats; piracetam at 400 mg/kg served as the comparator. A 2008 monkey study in Zhurnal Evolyutsionnoi Biokhimii i Fiziologii reported qualitative compensatory and antiamnestic effects of intranasal selank on neurosis-induced behavioral and memory disturbances; the abstract does not report quantitative outcomes. A parallel 2008 study by Kozlovskii and colleagues in Eksperimental'naia i Klinicheskaia Farmakologiia qualitatively reported recovery of learning and memory disrupted by neurotoxic noradrenergic-system damage in rats; the abstract does not report effect sizes. These studies are Russian-language and have not been replicated by independent Western groups, and the observed effects should be understood as preclinical rather than clinically translated.

What the clinical and preclinical research shows

The evidence base for selank is substantial by the standards of research peptides but skewed in an important way: the overwhelming majority of published studies are Russian-language, conducted at Russian research institutions, and indexed on PubMed only in abstract translation. No Western randomized controlled trials have been completed. Readers and providers should interpret all clinical claims as "Russian clinical data suggest" rather than conclusions drawn from an internationally replicated body of evidence. With that framing clearly in place, the available human data presents a reasonably coherent picture of an anxiolytic compound with a tolerability profile that differs meaningfully from benzodiazepines.

What the Human Evidence Looks Like

Clinical trials and their scope

The foundational clinical citation for selank's approved indications comes from a 2008 randomized comparative trial by Zozulia, Neznamov, and colleagues published in Zhurnal Nevrologii i Psikhiatrii. The trial enrolled 62 patients with generalized anxiety disorder and neurasthenia (30 on selank, 32 on medazepam), with outcomes measured by Hamilton, Zung, and Clinical Global Impression scales plus serum enkephalin activity. Selank produced anxiolytic activity that the authors characterized as similar to medazepam on Hamilton, Zung, and Clinical Global Impression scales, with additional antiasthenic effects and increased serum tau(1/2) leu-enkephalin that correlated with anxiety reduction. The English-language abstract does not report scale deltas, p-values, or responder rates; the comparison is qualitative. This trial formed part of the evidence base used by Russian regulators to approve selank for these indications.

Subsequent studies by Medvedev and colleagues compared selank to phenazepam, a high-potency Russian benzodiazepine. The 2014 trial in 60 patients with phobic-anxiety and somatoform disorders reported anxiolytic and mild nootropic effects of selank, with effect persistence approximately one week after the last dose; numeric scale changes were not reported in the English abstract. The 2015 follow-up in 70 patients combining selank with phenazepam reported faster onset of HDRS improvement and reduced incidence of phenazepam-attributable side effects (attention and memory impairment, sedation, increased sleep duration, sexual dysfunction); the abstract does not quantify the percentage of phenazepam dose reduction achieved.

Evidence limitations

Methodological caution is appropriate when reading this literature. The trials are small by Western RCT standards, conducted at single Russian sites, and have not been reproduced by independent research groups outside Russia. The clinical trial designs used medazepam and phenazepam as comparators, not placebo, which limits conclusions about absolute efficacy. No Phase 3 trials using CONSORT-compliant methodology with pre-registered endpoints have been published in any Western journal. The absence of Western replication is not evidence that the Russian findings are wrong, but it is a meaningful gap. Any clinical decision about selank should account for this evidence asymmetry explicitly.

Regulatory and Legal Status

FDA classification and Category 2 status

As of April 2026, selank is classified as an FDA Category 2 bulk drug substance under the agency's bulk drug substances for compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. Category 2 status means FDA is still evaluating whether selank is appropriate for compounding. During this review period, compounding pharmacies operating under Section 503A cannot use selank as a bulk ingredient. Selank has no FDA-approved indication for any use in the United States. It is approved for generalized anxiety disorder and neurasthenia only in the Russian Federation, where it is marketed as a prescription product.

What would need to change for availability to resume

For selank to return to legal compounding under Section 503A, FDA would need to either move it to Category 1 (eligible for compounding) following completion of its review or decline to restrict it. A manufacturer or sponsor could also submit an Investigational New Drug application to initiate US clinical trials, which could eventually lead to an NDA. Neither pathway has a clear timeline as of April 2026. State-level variation in enforcement of compounding regulations means the practical picture may differ across jurisdictions, but the federal Category 2 classification is the primary barrier to consistent access through compounding pharmacies.

What this means practically

Selank products sold through online vendors without a prescription are not regulated by the FDA. Independent testing of research peptide products has documented issues including incorrect concentrations, contamination, and misidentified compounds. This is not a theoretical concern: FDA warning letters to online peptide suppliers have cited precisely these product quality failures. Selank obtained outside a licensed compounding pharmacy with a valid prescription carries meaningful risk from these factors alone, separate from the compound's own safety profile.

Selank and Semax: Key Differences

Selank and Semax share a development lineage and are frequently discussed together, but they are distinct compounds with different primary mechanisms and research bases. Semax is a synthetic analog of adrenocorticotropic hormone (ACTH 4-7), developed at the same Moscow institute, and its primary studied effects center on BDNF upregulation, nootropic enhancement, and neuroprotection. Selank's primary studied effects are anxiolytic, with secondary immunomodulatory activity stemming from its tuftsin structural heritage. Research by Uchakina, Uchakin, and colleagues, published in 2008 in Zhurnal Nevrologii i Psikhiatrii, reported that selank at 10⁻⁷ M completely suppressed IL-6 gene expression in cultured peripheral blood cells from patients with depression but not in cells from healthy controls (p<0.05 for IL-6 concentration changes), and that 14 days of selank treatment in patients with GAD and neurasthenia produced significant inverse-correlated dynamics in serum Th1/Th2 cytokine balance. Fold-change and percent-change magnitudes were not reported in the English-language abstract. Additional mechanistic support comes from Kolomin and colleagues' 2014 English-language study in Molecular Immunology, which showed that selank modulates inflammation-related gene expression in a time-dependent manner, and from Ershov, Uchakin, and colleagues' 2009 paper in Voprosy Virusologii, which reported antiviral activity of selank in experimental influenza A (H3N2, A/Aichi 2/68) infection. Pre-inoculation administration in cell culture completely suppressed viral reproduction, and the same preventive scheme produced the highest survival rates in animal experiments; numeric survival percentages and viral titer reductions were not reported in the English-language abstract. The proposed mechanism involves IFN-α gene induction without modulation of IL-4, IL-10, or TNF-α. The two compounds are sometimes described as complementary pairings in Russian research contexts, but this pairing represents a research framing, not an FDA-validated protocol. There are no FDA-approved or clinically validated protocols for combining selank with any other compound.

Safety: What Is and Is Not Known

Clinical safety data

The Russian clinical trials generally report selank as well-tolerated. No significant sedation, no dependence signal over study periods, and no serious adverse events are described in the published abstracts. The intranasal delivery route, which is selank's primary administration pathway in clinical research, is characterized in a 2016 study by Vasileva, Kondrakhin, and colleagues in Eksperimental'naya i Klinicheskaya Farmakologiya showing that intranasal selank produced predominantly anxiolytic effects in BALB/c and C57BL/6 mice, in contrast to intraperitoneal administration which favored cognitive-enhancing effects. This route-dependent effect profile supports the preference for intranasal delivery in anxiety-focused use. However, the small trial sizes and limited follow-up durations mean that the full safety profile, particularly with extended use, is not established.

Risks from unregulated sources

Because selank lacks a US approval pathway, any product labeled as selank that is purchased outside a licensed pharmacy has received no FDA quality oversight. Manufacturing standards, purity, and accurate concentration are unknown for such products. The risks from contamination and incorrect dosing in unregulated research peptide products are well-documented in FDA enforcement communications and are not specific to selank. This is a structural risk of the unregulated supply chain, not a compound-specific toxicity concern.

Who Should Not Use Selank

Based on selank's proposed mechanisms, the following groups face elevated theoretical risk. No FDA-approved prescribing information exists to provide definitive contraindications; this list reflects mechanistic inference from available research.

• Individuals with known hypersensitivity to tuftsin or related peptides, given selank's structural derivation from tuftsin
• Individuals taking benzodiazepines or other GABAergic compounds without provider oversight, as selank's GABAergic modulation may interact with these agents in ways that are not fully characterized
• Pregnant or breastfeeding individuals, as safety in these populations has not been established in any available published research
• Individuals with active autoimmune conditions, given selank's documented cytokine-modulating activity; the clinical significance of this immunomodulation in autoimmune contexts is unknown
• Individuals with impaired renal or hepatic function, given the absence of pharmacokinetic data in these populations

Any provider considering selank for a patient would be making a clinical decision without the support of FDA-reviewed safety data. A full clinical evaluation, including relevant baseline bloodwork, would be necessary to assess individual risk.

Which Biomarkers Are Relevant if You Are Exploring Anxiety and Stress Biology?

Understanding the biological context for anxiety and stress-related symptoms helps frame what is happening in the body, regardless of which compounds are accessible at any given time. The markers below are clinically meaningful for anyone investigating the physiology underlying anxiety, mood, or stress responsivity.

• Cortisol: The primary adrenal stress hormone. Elevated or dysregulated cortisol levels are consistently associated with anxiety, disrupted sleep, and impaired cognitive function. Baseline and diurnal cortisol patterns provide direct insight into HPA axis activity, the same axis that selank's tuftsin heritage may modulate through its cytokine and immune effects.
• hs-CRP: High-sensitivity C-reactive protein reflects systemic inflammatory burden. Evidence linking neuroinflammation to anxiety and mood disorders has grown substantially over the past decade. Selank's documented cytokine-modulating effects, particularly on IL-6 and TNF-alpha, make this marker mechanistically relevant to understanding one dimension of anxiety biology.
• DHEA-S: Dehydroepiandrosterone sulfate is an adrenal hormone that functions as a functional counterbalance to cortisol. Low DHEA-S relative to cortisol is associated with chronic stress vulnerability, fatigue, and mood dysregulation. The cortisol-to-DHEA-S ratio provides a more complete picture of adrenal stress response than cortisol alone.
• Thyroid panel (TSH, free T3, free T4): Thyroid dysfunction, particularly subclinical hypothyroidism, frequently presents with anxiety, cognitive fog, and emotional dysregulation. Ruling out thyroid contribution to anxiety symptoms is a standard clinical step before attributing symptoms to primary anxiety disorders.
• Vitamin D (25-hydroxy): Low vitamin D status has been linked to increased anxiety and depressive symptoms across multiple observational and interventional studies. A 2023 systematic review and meta-analysis of 32 randomized trials of nutritional interventions (including vitamin D) in women during the menopausal transition, published in Menopause by Grigolon and colleagues, reported pooled effect sizes favoring intervention over placebo for both depressive symptoms (SMD −0.35; 95% CI −0.68 to −0.03; p=0.04) and anxiety symptoms (SMD −0.74; 95% CI −1.37 to −0.11; p=0.02), with significant heterogeneity across study designs. Vitamin D receptors are expressed in regions of the brain relevant to mood regulation, including the hippocampus.
• Complete blood count (CBC): Iron deficiency, even before anemia develops, can produce fatigue, cognitive impairment, and anxiety-like symptoms that may be misattributed to primary mental health conditions. A 2025 systematic review and meta-analysis of 18 studies (1,408 participants) in Neuroscience and Biobehavioral Reviews by Fiani and colleagues found that iron supplementation in non-anemic individuals improved anxiety (Cohen's d=0.34), fatigue (d=0.34), and short-term memory (d=0.53) in randomized trials, with effects absent in iron-replete subgroups. A complete blood count identifies this potentially reversible contributor.
• Magnesium (RBC): Intracellular magnesium depletion has been associated with heightened stress reactivity, muscle tension, and poor sleep. A 2017 systematic review of 18 supplementation trials in Nutrients by Boyle and colleagues found suggestive benefit on subjective anxiety in anxiety-vulnerable populations (positive findings in 4/8 mildly anxious samples and 4/7 premenstrual syndrome samples), though the authors flagged overall evidence quality as low and called for additional well-designed RCTs. Magnesium acts as a natural NMDA receptor antagonist, a pathway with functional overlap with anxiety regulation.

The Bottom Line

Selank's evidence base is real, more substantial than many research peptides, and clinically coherent in its primary claim: anxiolytic activity without the sedation and dependence profile of benzodiazepines. The English-language abstracts of the Russian comparative trials do not report quantitative effect sizes versus benzodiazepine comparators, which limits direct equivalence claims. The barrier to access in the United States is regulatory, not scientific. The FDA Category 2 classification reflects an incomplete review process, not a determination that selank is ineffective or unsafe. That said, the absence of Western RCTs means that clinical confidence in this compound rests on a body of Russian-language evidence that has not been independently verified. The honest framing is: promising, plausible, but incompletely characterized by the standards Western regulators require.

Whether or not selank becomes available through US compounding channels in the future, understanding the biology of anxiety through measurable markers is a rational starting point. That principle, testing first and building a biological baseline before any clinical decision, is central to Superpower's approach to preventive health: the belief that objective biomarker data should inform every conversation about wellbeing, regardless of which compounds are accessible at any given moment.

IMPORTANT SAFETY INFORMATION

Selank is not FDA-approved for any indication in the United States. It is approved only in the Russian Federation for generalized anxiety disorder and neurasthenia. As of April 2026, selank is classified as an FDA Category 2 bulk drug substance; compounding under Section 503A is restricted pending FDA review. Selank is currently unavailable through Superpower. Superpower is a technology platform that connects individuals with licensed providers; Superpower does not prescribe or dispense medications.

The safety and efficacy of selank have not been established through adequate and well-controlled clinical trials meeting FDA standards. Available clinical data are drawn from Russian-language studies that have not been replicated in Western populations. Long-term safety data are not available.

Based on proposed mechanisms, the following groups face elevated theoretical risk: individuals with known hypersensitivity to tuftsin or related peptides; individuals taking benzodiazepines or other GABAergic compounds without provider supervision; pregnant or breastfeeding individuals; individuals with active autoimmune conditions; individuals with impaired renal or hepatic function.

Warnings: GABAergic activity may interact with benzodiazepines and other CNS depressants; cytokine-modulating effects are of unknown clinical significance in autoimmune contexts; intranasal administration of unregulated products carries contamination and dosing inconsistency risk; the full side effect profile with extended human use is not characterized.

Common side effects (from Russian clinical data): generally reported as well-tolerated; mild nasal irritation with intranasal use has been noted; sedation is not a commonly reported effect, which distinguishes it from benzodiazepines in the available data. This is not a complete characterization of the safety profile.

Products labeled as selank that are sold through online vendors without a prescription have received no FDA quality oversight and carry risks including incorrect concentration, contamination, and misidentified compound identity. This is not theoretical: FDA warning letters to online peptide suppliers have documented these issues.

This is not a complete summary of safety information. Full FDA-approved prescribing information is not available for selank; compound reference data at PubChem CID 11765600.

Additional Questions

What is the FDA Category 2 peptide list?

FDA Category 2 is a classification applied to bulk drug substances being evaluated for eligibility under Section 503A of the Federal Food, Drug, and Cosmetic Act, which governs traditional compounding. Category 2 substances are under active review; compounding is restricted while that review is ongoing. Selank was placed in Category 2 as part of the broader February 2026 FDA reclassification review of peptide bulk drug substances. The full updated list is published on the FDA's website.

Are peptides legal again after the 2026 reclassification?

The February 2026 FDA reclassification did not make all peptides legal; it updated the categorical assignments of specific bulk drug substances under the compounding framework. Some peptides moved to Category 1 (eligible for compounding) and some remained in Category 2 (restricted pending review). Selank remains in Category 2 as of April 2026. Whether a specific peptide is legally available through US compounding pharmacies depends on its individual classification, not a blanket rule about peptides generally.

Will selank become available through compounding pharmacies again?

This depends on the outcome of FDA's Category 2 review process. If FDA moves selank to Category 1, compounding under Section 503A would resume. If the agency issues a final rule placing selank on the negative list, compounding would be permanently restricted. As of April 2026, no public timeline for this determination has been announced. Monitoring FDA's bulk drug substance rulemaking updates is the most reliable way to track this.